Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.15 – $0.25
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $82.2M | $92.5M | $51.6M | $617.0K | $49.9M | $18.1M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $20.2M | $82.2M | $92.5M | $51.6M | $617.0K | $49.9M | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% |
| R&D | $83.8M | $875.8M | $494.6M | $440.6M | $402.7M | $249.8M | $206.8M |
| Operating income | −$525.2M | −$897.0M | −$610.5M | −$513.8M | −$544.3M | −$403.9M | −$295.9M |
| EBITDA | −$124.1M | −$890.8M | −$602.8M | −$503.6M | −$168.2M | −$401.6M | −$290.3M |
| Net income | −$516.8M | −$1.21B | −$4.12B | −$484.3M | −$174.8M | −$508.2M | −$216.9M |
| Net margin | -2559.1% | -1467.2% | -4452.3% | -938.1% | -28335.3% | -1017.6% | -1196.6% |
| EPS (diluted) | -0.73 | -1.71 | -9.48 | -0.67 | -0.24 | -0.70 | -0.30 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $310M | $-0.44 | $-0.44–$-0.44 | 1 |
| 2027 | $434M | $-0.43 | $-0.43–$-0.43 | 1 |
| 2028 | $2.2B | $-0.34 | $-0.34–$-0.34 | 1 |
| 2029 | $5M | $-0.33 | $-0.33–$-0.33 | 1 |
Forward consensus · source: Financial Modeling Prep
BRII BIOSCIENCE LTD
No one on the platform currently holds BRIBF.
No tracked institution reports a position in BRIBF as of their last filing.
No one on the platform has traded BRIBF yet.
| $539M |
| — |
| IPHYFInnate Pharma S.A. | $1.65 | +0.00% | $155M | — |
| JWCTFJW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $99M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.6× sales vs its 14.1× historical median P/S.
Fair value ≈ $3.49 · price $0.15 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.